TEMPO.CO, Jakarta - The Medicine Faculty of Padjadjaran University ensured that volunteers for the third-phase clinical trial of the COVID-19 vaccine, that was developed in cooperation with China-based pharmaceutical firm Sinovac Biotech, will be provided with insurance.
“During the study, they will get insurance and are not paid because they volunteered,” said the research team head, Kusnandi Rusmil, in a press conference at the university hospital in Bandung, Wednesday, July 22.
He said that after doctors injected the vaccine, the team would monitor the volunteers. “We will monitor closely, for three days, five days, 14 days, and so on. If they are sick, whether the symptom of the vaccine or not, they will see another doctor, and I will ask the doctor more deeply,” Kusnandi said.
According to Kusnandi, many people have volunteered for the clinical trial thus far. Some of them are employees and doctors from Jakarta hospitals.
“But I refused [their proposals] because they do not live in Bandung. It will be difficult for us to monitor,” he added.
Meanwhile, the team manager Eddy Fadlyana said that the third-phase clinical trial of the COVID-19 vaccine will be conducted in six places in Bandung City: four community health centers or Puskesmas, the university health center, and the university hospital.